(Q39390183)

English

Celecoxib and tauro-ursodeoxycholic acid co-treatment inhibits cell growth in familial adenomatous polyposis derived LT97 colon adenoma cells

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Celecoxib and tauro-ursodeoxycholic acid co-treatment inhibits cell growth in familial adenomatous polyposis derived LT97 colon adenoma cells (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

1 reference

based on heuristic

inferred from title

familial adenomatous polyposis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Fokko M Nagengast

5

object named as

Fokko M Nagengast

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Hennie M J Roelofs

2

object named as

Hennie M J Roelofs

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Bjorn W H van Heumen

1

object named as

Bjorn W H van Heumen

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

author name string

René H M Te Morsche

3

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Brigitte Marian

4

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Wilbert H M Peters

6

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

language of work or name

0 references

publication date

14 February 2012

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Experimental Cell Research

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

318

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

819-827

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Localization of the gene for familial adenomatous polyposis on chromosome 5.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.004

7 January 2021

Results of national registration of familial adenomatous polyposis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.004

7 January 2021

Changing causes of mortality in patients with familial adenomatous polyposis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.004

7 January 2021

Evaluating causes of death in familial adenomatous polyposis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.004

7 January 2021

Duodenal adenomatosis in familial adenomatous polyposis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.004

7 January 2021

Decision analysis in the management of duodenal adenomatosis in familial adenomatous polyposis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.004

7 January 2021

Worldwide survey among polyposis registries of surgical management of severe duodenal adenomatosis in familial adenomatous polyposis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.004

7 January 2021

Features of duodenal cancer in patients with familial adenomatous polyposis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.004

7 January 2021

Pancreas-preserving total duodenectomy versus standard pancreatoduodenectomy for patients with familial adenomatous polyposis and polyps in the duodenum

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.004

7 January 2021

The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.004

7 January 2021

Celecoxib for the prevention of colorectal adenomatous polyps

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.004

7 January 2021

Celecoxib for the prevention of sporadic colorectal adenomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.004

7 January 2021

Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.004

7 January 2021

The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.004

7 January 2021

Population breast-cancer screening

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.004

7 January 2021

A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.004

7 January 2021

Tauroursodeoxycholic acid protects in vitro models of human colonic cancer cells from cytotoxic effects of hydrophobic bile acids

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.004

7 January 2021

Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.004

7 January 2021

Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.004

7 January 2021

Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.004

7 January 2021

Ursodeoxycholic acid suppresses Cox-2 expression in colon cancer: roles of Ras, p38, and CCAAT/enhancer-binding protein.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.004

7 January 2021

Ursodeoxycholate/Sulindac combination treatment effectively prevents intestinal adenomas in a mouse model of polyposis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.004

7 January 2021

Cells obtained from colorectal microadenomas mirror early premalignant growth patterns in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.004

7 January 2021

Biliary bile acid profiles in patients with familial adenomatous polyposis before and after colectomy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.004

7 January 2021

Ursodeoxycholic acid intervention in patients with familial adenomatous polyposis: a pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.004

7 January 2021

Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.004

7 January 2021

COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.004

7 January 2021

The anti-proliferative potency of celecoxib is not a class effect of coxibs

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.004

7 January 2021

Down-regulation of PGE2 by physiologic levels of celecoxib is not sufficient to induce apoptosis or inhibit cell proliferation in human colon carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.004

7 January 2021

Optimization of chemically defined cell culture media--replacing fetal bovine serum in mammalian in vitro methods.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.004

7 January 2021

Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.004

7 January 2021

Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.004

7 January 2021

Bile acid induced gene expression in LT97 colonic adenoma cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.004

7 January 2021

Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.004

7 January 2021

Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.004

7 January 2021

Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.004

7 January 2021

Identifiers

10.1016/J.YEXCR.2012.02.004

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39390183&oldid=2164767058"